Supreme Court denies cert to J&J subsidiary, Janssen Biotech, in Humira case

Health.yahoo noted that the Supreme Court declined to review a decision of the Court of Appeals for the Federal Circuit that was adverse to J&J:

The appeals court ruled the patent claims asserted by the J&J unit were invalid and the patent thus could not be infringed. It overturned the award of $1.67 billion by a jury in 2009 in federal court in Texas for lost profits and damages.

The brief on behalf of Abbott. addresses the "written description" issues.

In addition to Janssen, New York University was also a losing petitioner.